Abeona Therapeutics (NASDAQ:ABEO) Director Christine Berni Silverstein Sells 20,070 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Christine Berni Silverstein sold 20,070 shares of Abeona Therapeutics stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $5.09, for a total transaction of $102,156.30. Following the transaction, the director directly owned 137,722 shares of the company’s stock, valued at $701,004.98. This represents a 12.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Abeona Therapeutics Trading Down 3.6%

ABEO traded down $0.19 during trading on Wednesday, reaching $5.08. 1,152,880 shares of the stock traded hands, compared to its average volume of 1,248,534. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average is $5.17 and its 200 day moving average is $5.58. Abeona Therapeutics Inc. has a 12 month low of $3.93 and a 12 month high of $7.54. The stock has a market capitalization of $275.29 million, a PE ratio of 4.13 and a beta of 1.18.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. Equities analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ABEO. Wall Street Zen cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a report on Monday, October 13th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Abeona Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in shares of Abeona Therapeutics during the second quarter worth approximately $25,000. Legal & General Group Plc bought a new stake in Abeona Therapeutics during the 2nd quarter valued at $27,000. Russell Investments Group Ltd. bought a new stake in Abeona Therapeutics during the 3rd quarter valued at $37,000. Legato Capital Management LLC acquired a new position in Abeona Therapeutics during the third quarter worth $57,000. Finally, SG Americas Securities LLC bought a new position in shares of Abeona Therapeutics in the fourth quarter valued at $57,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.